Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
The cell line expresses CD7, CD4, CD13, CD33, CD34, HLA-DR and c-Kit on cell surface compatible with that of acute myelocytic leukemia, subtype M0 (AML-M0).
Kasumi-3 has t(3;7)(q27:q22), del(5)(q15), del(9)(q32), and add(12)(p11) chromosomal abnormalities. The breakpoint of 3q27 is located near the EVI1 gene.
A high level of expression of the EVI1 gene was observed.
Kasumi-3 cells treated with TPA showed maturation to monocytic lineage.
Treatment with either interleukin (IL)-2, IL-3, IL-4, granulocyte-macrophage colony-stimulating factor (GMCSF) or stem cell factor induced the proliferation, characteristic of undifferentiated leukemia.
Asou H, et al. Establishment of an undifferentiated leukemia cell line (Kasumi-3) with t(3;7)(q27;q22) and activation of the EVI1 gene. Jpn. J. Cancer Res. 87: 269-274, 1996. PubMed: 8613429
Mochizuki N, et al. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood 96: 3209-3214, 2000. PubMed: 11050005
Suzukawa K, et al. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26). Genomics 42: 356-360, 1997. PubMed: 9192861
Suzukawa K, et al. Activation of EVI1 transcripts with chromosomal translocation joining the TCRVbeta locus and the EVI1 gene in human acute undifferentiated leukemia cell line (Kasumi-3) with a complex translocation of der(3)t(3;7;8). Leukemia 13: 1359-1366, 1999. PubMed: 10482986
